This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the pilot episode of The Human Side of Clinical Trials, Brian McGowan, PhD, chief learning officer and co-founder of ArcheMedX, introduced a framework showing why operational failures in trials often trace to gaps in human readiness rather than process design. When enrollment falls behind, protocol deviations increase, or sites struggle after activation, organizations must ask whether people were adequately prepared and equipped with genuine understanding, not just information.
- Fortrea announced the acquisition of Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in all-cash, adding a 200-bed clinical pharmacology unit, a bioanalytical laboratory, and biospecimen storage in Texas. The combination reduces handoffs between clinical and bioanalytical functions, improves turnaround times, and enables sponsors to run larger studies with greater operational flexibility.
- In a new contributed article, Partha Anbil and Anamika Krishanpal examined how 80% to 85% of trials miss enrollment timelines with trial delays costing $600,000 to $800,000 per day in lost revenue. AI-enabled patient matching and EHR integration are becoming operational levers, but bias, explainability, and governance will determine whether the technology scales across diverse patient populations.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
